The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status

Thierry André, Timothy Iveson, Roberto Labianca, Jeffrey A. Meyerhardt, Ioannis Souglakos, Takayuki Yoshino, James Paul, Alberto Sobrero, Julien Taieb, Anthony F. Shields, Atsushi Ohtsu, Axel Grothey, Daniel J. Sargent

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Fingerprint

Dive into the research topics of 'The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status'. Together they form a unique fingerprint.

Medicine & Life Sciences